Abstract
This review focuses on Eating Disorders (ED), the role played by neurotransmitters and peptides in ED phenomena as well as the drugs used in the treatment of these diseases. For ED, we mean a syndrome characterized by persistent alteration of eating behavior and the conditions that cause an insufficient ingestion and/or adsorption of foods. There are three different ED diseases: Anorexia Nervosa (AN), Bulimia Nervosa (BN) and Binge Eating Disorders (BED). ED are complex conditions that arise from a combination of long-standing behavioral, emotional, psychological, interpersonal, and social factors. The neuronal circuits that control the ingestion of food are mainly related to catecholaminergic, serotoninergic and peptidergic systems. In this respect, while serotonin, dopamine and prostaglandin promote the ingestion of food, by contrast, neuropeptide Y, norepinephrine, GABA and opioid peptides inhibit food ingestion, thus, causing the occurence of ED. The drugs mainly used in the treatment of ED are antidepressants such as selective serotonin reuptake inhibitors and tricyclic antidepressants. Additionally, mood stabilizers (lithium), anxiolytics, serotonin and noradrenalin reuptake inhibitors and antipsychotic drugs are often used in the treatment of ED.
Keywords: Eating disorders, anorexia nervosa, bulimia nervosa, binge eating disorders
Reviews on Recent Clinical Trials
Title: Recent Clinical Aspects of Eating Disorders
Volume: 4 Issue: 1
Author(s): Anna Capasso, Claudio Petrella and Walter Milano
Affiliation:
Keywords: Eating disorders, anorexia nervosa, bulimia nervosa, binge eating disorders
Abstract: This review focuses on Eating Disorders (ED), the role played by neurotransmitters and peptides in ED phenomena as well as the drugs used in the treatment of these diseases. For ED, we mean a syndrome characterized by persistent alteration of eating behavior and the conditions that cause an insufficient ingestion and/or adsorption of foods. There are three different ED diseases: Anorexia Nervosa (AN), Bulimia Nervosa (BN) and Binge Eating Disorders (BED). ED are complex conditions that arise from a combination of long-standing behavioral, emotional, psychological, interpersonal, and social factors. The neuronal circuits that control the ingestion of food are mainly related to catecholaminergic, serotoninergic and peptidergic systems. In this respect, while serotonin, dopamine and prostaglandin promote the ingestion of food, by contrast, neuropeptide Y, norepinephrine, GABA and opioid peptides inhibit food ingestion, thus, causing the occurence of ED. The drugs mainly used in the treatment of ED are antidepressants such as selective serotonin reuptake inhibitors and tricyclic antidepressants. Additionally, mood stabilizers (lithium), anxiolytics, serotonin and noradrenalin reuptake inhibitors and antipsychotic drugs are often used in the treatment of ED.
Export Options
About this article
Cite this article as:
Capasso Anna, Petrella Claudio and Milano Walter, Recent Clinical Aspects of Eating Disorders, Reviews on Recent Clinical Trials 2009; 4 (1) . https://dx.doi.org/10.2174/157488709787047594
DOI https://dx.doi.org/10.2174/157488709787047594 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Leishmaniasis: A Review and Assessment of Recent Research
Current Pharmaceutical Design Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
Current Pharmaceutical Design Endocrinological Aspects of Proteinuria and Podocytopathy in Diabetes: Role of the Aldosterone/Mineralocorticoid Receptor System
Current Diabetes Reviews Transfusion-related Acute Lung Injury: An Overview
Current Pharmaceutical Design Letter to the Editor Regarding Recent Current Cardiology Review “Cardiac Arrest in the Cardiac Catheterization Laboratory” by Yadav and Truong
Current Cardiology Reviews Small Animal Computed Tomography Imaging
Current Medical Imaging Point of Care Cardiac Ultrasound Applications in the Emergency Department and Intensive Care Unit - A Review
Current Cardiology Reviews MicroRNAs and Physical Activity
MicroRNA Vascular Disease and Risk Factors in Chronic Kidney Disease
Vascular Disease Prevention (Discontinued) C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design Medication Adherence and Associated Factors among Chronic Heart Failure Clients on Follow Up Oromia Region, West Ethiopia
Cardiovascular & Hematological Agents in Medicinal Chemistry Metabolic and Functional Brain Mapping, Connectivity and Plasticity Applied to the Surgery of Cerebral Tumors
Current Medical Imaging Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis
Current Pharmaceutical Biotechnology Oxytocin in the Heart Regeneration
Recent Patents on Cardiovascular Drug Discovery Effect of Cabergoline on Cognitive Impairments in Transgenic <i>Drosophila</i> Model of Parkinson’s Disease
Letters in Drug Design & Discovery Natural Molecules as Talented Inhibitors of Nucleotide Pyrophosphatases/ Phosphodiesterases (PDEs)
Current Topics in Medicinal Chemistry Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension
Current Pharmaceutical Design The Effect of Dual-Task Testing on Balance and Gait Performance in Adults with Type 1 or Type 2 Diabetes Mellitus: A Systematic Review
Current Diabetes Reviews